PMID- 17393073
OWN - NLM
STAT- MEDLINE
DCOM- 20071105
LR  - 20181113
IS  - 0167-6997 (Print)
IS  - 0167-6997 (Linking)
VI  - 25
IP  - 5
DP  - 2007 Oct
TI  - Phase II study of Triapine in patients with metastatic renal cell carcinoma: a 
      trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC 
      IND.161).
PG  - 471-7
AB  - Triapine is a novel small molecule ribonucleotide reductase inhibitor that showed 
      activity in renal cell carcinoma (RCC) cell lines. Evaluating new agents with 
      novel mechanisms remains of interest for patients with incurable RCC. This was a 
      single-arm, multicentre phase II trial where Triapine was given at a schedule of 
      96 mg/m2 2-h infusion daily x 4 repeated every 2 weeks in patients with recurrent 
      RCC. A median of four cycles of Triapine was administered to 19 eligible 
      patients. One response was seen (7%.) Median time to progression was 3.6 months. 
      Common adverse events (AEs) were grade 1-2, with fatigue in 74%, nausea in 68% 
      and vomiting in 58%. However grade 3/4 neutropenia was seen in 79% and acute 
      reactions of hypoxia, hypotension, methemoglobinemia were seen. Dose 
      reductions/delays due to AEs were common with only 47% of patients receiving > 
      90% of planned dose intensity. The study closed, at the end of stage 1 as it did 
      not meet the minimal efficacy criteria to proceed. Further evaluation of Triapine 
      at this dose and schedule in patients with advanced kidney cancer is not 
      recommended.
FAU - Knox, Jennifer J
AU  - Knox JJ
AD  - Department of Medical Oncology, University Health Network-OCI/Princess Margaret 
      Hospital, 610 University Avenue, Toronto, ON, M5G 2M9, Canada. 
      jennifer.knox@uhn.on.ca
FAU - Hotte, Sebastien J
AU  - Hotte SJ
FAU - Kollmannsberger, Christian
AU  - Kollmannsberger C
FAU - Winquist, Eric
AU  - Winquist E
FAU - Fisher, Bryn
AU  - Fisher B
FAU - Eisenhauer, Elizabeth A
AU  - Eisenhauer EA
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20070328
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 0 (Thiosemicarbazones)
RN  - 143621-35-6 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone)
RN  - EC 1.17.4.- (Ribonucleotide Reductases)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Canada
MH  - Carcinoma, Renal Cell/*drug therapy
MH  - Clinical Trials as Topic
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Ribonucleotide Reductases/antagonists & inhibitors
MH  - Thiosemicarbazones/adverse effects/*therapeutic use
MH  - Treatment Outcome
EDAT- 2007/03/30 09:00
MHDA- 2007/11/06 09:00
CRDT- 2007/03/30 09:00
PHST- 2007/01/12 00:00 [received]
PHST- 2007/02/20 00:00 [accepted]
PHST- 2007/03/30 09:00 [pubmed]
PHST- 2007/11/06 09:00 [medline]
PHST- 2007/03/30 09:00 [entrez]
AID - 10.1007/s10637-007-9044-9 [doi]
PST - ppublish
SO  - Invest New Drugs. 2007 Oct;25(5):471-7. doi: 10.1007/s10637-007-9044-9. Epub 2007 
      Mar 28.